CancelGroupGroup 2Fill 1Page 1Group 13Group 9search iconStroke 4164 + Stroke 4165GroupPage 1Dark Line Arrowtwiiter icoPage 1Page 1


Fast access to useful resources and the narrative report of this mapping site.

Resource Quicklinks

The following resources provide additional insight and information on the global landscape, including current challenges and opportunities, confronting TB care and IQA-SLD supply and access.

Narrative Analysis

Download the narrative analysis of this initiative's findings. This data is current as of September 2017.

We recommend using Google Chrome or Windows Edge for the best experience of the TB Drug Access Atlas. Otherwise, please update your browser to the most current version to optimize this site’s features. 

Internationally quality-assured (IQA) second-line drugs (SLDs) are essential to treat and cure drug resistant forms of tuberculosis, which infects half a million people annually and is responsible for close to 250,000 deaths per year. However, these drugs are often the least accessible to the populations that need them most.

This mapping tool uses data regarding ongoing and planned work to address IQA SLD supply and demand as reported by stakeholders from the mapping research project, alongside the burden of multidrug-resistant tuberculosis (MDR-TB) according to World Health Organization reports. By highlighting the areas of greatest MDR-TB burden and the areas of activity, this tool is meant to inform decision-making and encourage the sharing of experiences and resources among initiates operating in the same geographical and market areas to improve access to MDR-TB pharmaceuticals. Moreover, as this tool continues to grow in support and collaboration with stakeholders in the IQA SLD landscape, it will be updated regularly to reflect change and growth in the MDR-TB landscape.